MRUS Merus
- 56.550
- -1.100-1.91%
- 56.600
- +0.050+0.09%
Merus News
Merus(MRUS.US) Officer Sells US$475.46K in Common Stock
$Merus(MRUS.US)$ Officer Shuman Harry sold 8,300 shares of common stock on Jun 10, 12, 2024 at an average price of $57.284 for a total value of $475.46K.Source: Announcement What is statement of chang
Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing
Harry Shuman, Vice President, Controller, Principal Accounting Officer, on June 10, 2024, sold 8,300 shares in Merus (MRUS) for $475,456. Following the Form 4 filing with the SEC, Shuman has control o
Merus(MRUS.US) Officer Sells US$317.35K in Common Stock
$Merus(MRUS.US)$ Officer Shuman Harry sold 6,000 shares of common stock on Jun 4, 2024 at an average price of $52.892 for a total value of $317.35K.Source: Announcement What is statement of changes in
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $76
BofA Securities analyst Tazeen Ahmad maintains $Merus(MRUS.US)$ with a buy rating, and maintains the target price at $76.According to TipRanks data, the analyst has a success rate of 48.3% and a total
Merus Is Maintained at Buy by B of A Securities
Merus Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Merus, Lowers Price Target to $76
B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $80 to $76.
Express News | Merus NV : BofA Global Research Cuts Price Objective to $76 From $80
Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating
Merus (MRUS) has an average buy rating and price target range of $54 to $93, according to analysts polled by Capital IQ. Price: 53.00, Change: +0.05, Percent Change: +0.10
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Cuts Target Price to $76
BofA Securities analyst Tazeen Ahmad maintains $Merus(MRUS.US)$ with a buy rating, and adjusts the target price from $80 to $76.According to TipRanks data, the analyst has a success rate of 48.3% and
Merus Is Maintained at Buy by Truist Securities
Merus Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Merus, Raises Price Target to $88
Merus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 70.05% Truist Securities $69 → $88 Maintains Buy 05/29/2024 54.59% B of A Securities $61 → $80
Express News | Merus NV : BMO Raises Target Price to $91 From $84
Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment
Merus (MRUS) said Monday that its MCLA-129 product candidate demonstrated a reduction in target lesion tumor size in 80% of patients with certain types of non-small-cell lung cancer who were available
Express News | Merus' MCLA-129 Demonstrates Single-Agent Efficiency In METex14 NSCLC In Poster Presentation At ASCO 2024
Express News | Merus NV : Truist Securities Raises Target Price to $88 From $69
Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche
DelveInsight's Bispecifics/Trispecifics Market Insights report includes a comprehensive understanding of current treatment practices, emerging...
Express News | Merus NV : Jefferies Raises Target Price to $77 From $57
Merus Presented Interim Data On MCLA-145 Monotherapy And In Combination With Pembrolizumab At ASCO 2024
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced upd
Express News | Merus NV : Leerink Partners Raises Target Price to $88 From $65
Analysis
Price Target
No Data
